CD79A Antibody (JCB117) - IHC-Prediluted
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-44736
Clone JCB117 was used by HLDA to establish CD designation.
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # JCB117
Format
IHC-Prediluted
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of human CD79a protein.
Localization
Cell surface
Specificity
A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Marker
B-Cell Marker
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Theoretical MW
44 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Description
The prediluted antibody does not require any mixing, dilution, reconstitution, or titration; the antibody is ready-to-use and optimized for staining.
Scientific Data Images for CD79A Antibody (JCB117) - IHC-Prediluted
Immunohistochemistry-Paraffin: CD79A Antibody (JCB117) - IHC-Prediluted [NBP2-44736]
Immunohistochemistry-Paraffin: CD79A Antibody (JCB117) - IHC-Prediluted [NBP2-44736] - Formalin-fixed, paraffin-embedded human Tonsil stained with CD79A Antibody (JCB117).Applications for CD79A Antibody (JCB117) - IHC-Prediluted
Application
Recommended Usage
Immunohistochemistry-Paraffin
1:100-1:200
Application Notes
Immunohistochemistry (Formalin-fixed): 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
Optimal dilution for a specific application should be determined.
Optimal dilution for a specific application should be determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10 mM PBS with 0.05% BSA
Format
IHC-Prediluted
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: CD79A
Alternate Names
CD79A, MB-1
Gene Symbol
CD79A
Additional CD79A Products
Product Documents for CD79A Antibody (JCB117) - IHC-Prediluted
Product Specific Notices for CD79A Antibody (JCB117) - IHC-Prediluted
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...